1. Define treatment refractory anxiety.
2. Describe two common comorbidities of treatment refractory anxiety.
3. Discuss two possible approaches to treatment for treatment refractory
anxiety.
4. Identify the most appropriate response to a client who states that
they use marijuana to manage their anxiety. Discuss the education
the PMHNP should provide.
5. Identify the most appropriate response to a client who states that
they use Silexan to manage their anxiety. Discuss the education
the PMHNP should provide?
1. Treatment refractory anxiety is anxiety that has been ineffectively treated with standard
anxiety disorder treatments, specifically unresponsive to at least one antidepressant given for
an adequate period of time as an adequate or appropriate dose for the patient [ CITATION
Ela20 \l 1033 ].
2. One common comorbidity of treatment refractory anxiety is substance use disorder. Similar
symptoms to anxiety disorder may appear when a person is experiencing a substance use
disorder. Because anxiety disorders modify the presenting symptoms and treatment of
substance use disorders and vice versa, individuals may be at increased risk for relapse and
poor outcomes related to poor adherence to treatment or self-medicating through illegal
substances [ CITATION Cam21 \l 1033 ].
Another common comorbidity is depression, specifically a diagnosis of major depressive
disorder. Symptoms of anxiety appear to be worse in patients with MDD as a diagnosis
and research believes this may be related to pseudo-resistance, also known as poor
medication adherence [ CITATION Pet22 \l 1033 ]. One study shows that patients who are
2. Describe two common comorbidities of treatment refractory anxiety.
3. Discuss two possible approaches to treatment for treatment refractory
anxiety.
4. Identify the most appropriate response to a client who states that
they use marijuana to manage their anxiety. Discuss the education
the PMHNP should provide.
5. Identify the most appropriate response to a client who states that
they use Silexan to manage their anxiety. Discuss the education
the PMHNP should provide?
1. Treatment refractory anxiety is anxiety that has been ineffectively treated with standard
anxiety disorder treatments, specifically unresponsive to at least one antidepressant given for
an adequate period of time as an adequate or appropriate dose for the patient [ CITATION
Ela20 \l 1033 ].
2. One common comorbidity of treatment refractory anxiety is substance use disorder. Similar
symptoms to anxiety disorder may appear when a person is experiencing a substance use
disorder. Because anxiety disorders modify the presenting symptoms and treatment of
substance use disorders and vice versa, individuals may be at increased risk for relapse and
poor outcomes related to poor adherence to treatment or self-medicating through illegal
substances [ CITATION Cam21 \l 1033 ].
Another common comorbidity is depression, specifically a diagnosis of major depressive
disorder. Symptoms of anxiety appear to be worse in patients with MDD as a diagnosis
and research believes this may be related to pseudo-resistance, also known as poor
medication adherence [ CITATION Pet22 \l 1033 ]. One study shows that patients who are
